NE-3107 is under clinical development by BioVie and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how NE-3107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NE-3107 (Triolex, HE3286) is under development for the treatment of Alzheimer's disease, multiple myeloma, early stage prostate cancer, castration resistant prostate cancer and Parkinson's disease. The drug candidate is administered through oral route. The drug candidate is developed based on hormonal signaling technology platform. It acts by targeting ERK 1AND 2 (Extracellular Signal Regulated Kinase 1 and 2). The drug candidate was also under development for the treatment of inflammatory diseases, systemic lupus erythematosus, cystic fibrosis, type 2 diabetes, L-dopa induced dyskinesia, rheumatoid arthritis, ulcerative colitis and multiple sclerosis.
BioVie (BIVI) is a clinical-stage biopharmaceutical company that develops drug therapies for liver disease. The company’s pipeline products such as BIV201 (continuous infusion terlipressin) and clinical trial for ascites due to advanced liver cirrhosis. BIV201 for hepatorenal syndrome (HRS). It focused on potential future treatment option patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, NASH and alcoholism. The company is also focused on the FDA to approve their drug specifically for treating ascites to extend their quality. BioVie is targeting this landmark achievement. BIVI is headquartered in Santa Monica, California, the US.
For a complete picture of NE-3107’s drug-specific PTSR and LoA scores, buy the report here.